Chemomab Therapeutics
CMMB
5 hedge funds and large institutions have $1.51M invested in Chemomab Therapeutics in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 5 closing their positions.
0% more ownership
Funds ownership: 0.04% → 0.05% (+0%)
34% less capital invested
Capital invested by funds: $2.28M → $1.51M (-$768K)
44% less funds holding
Funds holding: 9 → 5 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$592K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$295K |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$57.8K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$50K |
| 4 |
VF
Virtu Financial
New York
|
-$30K |
| 5 |
Morgan Stanley
New York
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIH
1
Meitav Investment House
Bene-Beraq,
Israel
| $521K | -$57.8K | -478 | -8% |
|
|
PCM
2
Palisade Capital Management
Fort Lee,
New Jersey
| $517K | – | – | – |
|
|
AIC
3
AWM Investment Company
New York
| $438K | +$592K | +4,890 | New |
|
|
PF
4
Phoenix Financial
Givatayim,
Israel
| $36K | – | – | – |
|
|
KCM
5
Kennedy Capital Management
St Louis,
Missouri
| – | -$295K | -2,006 | Closed |
|
|
6
Fidelity Investments
Boston,
Massachusetts
| – | -$50K | -339 | Closed |
|
|
VF
7
Virtu Financial
New York
| – | -$30K | -204 | Closed |
|
|
8
Morgan Stanley
New York
| – | -$25K | -170 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$484 | -4 | -67% |
|
CMMB Hedge Fund Activity: Q4 2019 in Review
5 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q4 2019, worth a combined $1.51M — down 34% from $2.28M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CMMB and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was AWM Investment Company, opening a new position worth an estimated $592K. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $295K sold.
- 5 institutional investors held Chemomab Therapeutics (CMMB) as of Q4 2019, down from 9 in Q3 2019.
- Funds reported $1.51M of Chemomab Therapeutics stock for Q4 2019, down 34% quarter-over-quarter.
- 1 fund opened new Chemomab Therapeutics positions in Q4 2019 and 5 closed out, a net change of -4 holders.
- The largest Chemomab Therapeutics buyer in Q4 2019 was AWM Investment Company, an estimated $592K added.
- The largest Chemomab Therapeutics seller in Q4 2019 was Kennedy Capital Management, an estimated $295K sold.
Based on aggregated 13F filings for Q4 2019.